Fresenius Medical cuts top end of 2026 profit outlook

By Reuters News

- German dialysis specialist Fresenius Medical Care FMEG.DE cut the upper end of its 2026 operating income outlook on Tuesday, citing regulatory and inflation headwinds after reporting third-quarter results.

It now expects 2026 operating income to range from flat to a mid-single-digit percentage decline, compared with its previous forecast for a mid-single-digit percentage decline to a mid-single-digit increase.

  • Third-quarter operating income excluding special items fell 5% to €545 million ($610 million) from €574 million a year earlier, compared with Vara Research consensus of €518 million.

  • US same-market treatments declined 1.1%, accelerating from declines of 0.4% in the first quarter and 0.9% in the second quarter.

  • Revenue grew 1% to €4.94 billion from €4.89 billion a year earlier.

  • The results come weeks after Shervin J. Korangy became CEO as FMC seeks to revive growth following years of restructuring efforts.

https://www.reuters.com/graphics/FRESENIUSMEDICALCARE-RESULTS/dwpkmbmxapm/chart.png

($1 = 0.8937 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.